GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » Cost of Goods Sold

PDS Biotechnology (PDS Biotechnology) Cost of Goods Sold : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology Cost of Goods Sold?

PDS Biotechnology's cost of goods sold for the three months ended in Mar. 2024 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PDS Biotechnology's Gross Margin % for the three months ended in Mar. 2024 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.


PDS Biotechnology Cost of Goods Sold Historical Data

The historical data trend for PDS Biotechnology's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Cost of Goods Sold Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PDS Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PDS Biotechnology Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology  (NAS:PDSB) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PDS Biotechnology's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

PDS Biotechnology's Inventory Turnover for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


PDS Biotechnology Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (PDS Biotechnology) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Executives
Spencer D. Brown officer: Senior VP, General Counsel 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill officer: Chief Financial Officer C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist director, 10 percent owner RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King officer: Interim Chief Financial Office 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev director 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk officer: Principal Accounting Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes director C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo director, 10 percent owner, officer: President/CEO 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood officer: Chief Medical Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn officer: Chief Scientific Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

PDS Biotechnology (PDS Biotechnology) Headlines

From GuruFocus